Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pharmacological therapy in erectile dysfunction--current standards and new viewpoint]

D Schultheiss1, C G Stief, M C Truss

  • 1Klinik für Urologie, Medizinischen Hochschule Hannover, Deutschland.

Wiener Medizinische Wochenschrift (1946)
|January 1, 1997
PubMed
Summary

Intracavernous pharmacotherapy for erectile dysfunction (ED) is evolving. New research focuses on nitric oxide and phosphodiesterase inhibitors, alongside novel drug delivery methods for ED treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.

Frontiers in pharmacology·2024
Same author

[Urinary diversion for acute epididymitis : Transurethral or suprapubic catheter?]

Urologie (Heidelberg, Germany)·2022
Same author

[Enhanced Recovery After Surgery (ERAS®) after radical cystectomy-current data].

Der Urologe. Ausg. A·2021
Same author

<sup>18</sup>F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results.

European journal of nuclear medicine and molecular imaging·2020
Same author

[The role of the microbiome in urology].

Der Urologe. Ausg. A·2020
Same author

[The microbiome in benign prostatic hyperplasia].

Der Urologe. Ausg. A·2020

Area of Science:

  • Pharmacology
  • Urology
  • Molecular Biology

Context:

  • Intracavernous pharmacotherapy, particularly with prostaglandin E1 (PGE1), is a long-established treatment for erectile dysfunction (ED).
  • Recent research explores intracellular mechanisms of smooth muscle relaxation in penile cavernous tissue, crucial for erection.
  • Nitric oxide (NO) and phosphodiesterase (PDE) isoenzymes are identified as key players in these mechanisms.

Purpose:

  • To review current advancements in intracavernous pharmacotherapy for erectile dysfunction.
  • To highlight the role of nitric oxide and phosphodiesterase inhibitors in ED treatment.
  • To discuss emerging drug delivery strategies for erectile dysfunction.

Summary:

  • Prostaglandin E1 (PGE1) remains a standard intracavernous agent for ED due to its favorable side effect profile.

Related Experiment Videos

  • Nitric oxide donors (e.g., linsidomine) and oral phosphodiesterase inhibitors (e.g., sildenafil) are under clinical investigation.
  • Novel administration routes, including transdermal and intraurethral applications, are being explored for ED pharmacotherapy.

    • Impact:

    • Advances in understanding smooth muscle relaxation mechanisms are driving new ED treatment options.
    • The development of targeted therapies like NO donors and PDE inhibitors offers improved efficacy for erectile dysfunction.
    • Exploring new drug delivery systems aims to enhance patient compliance and treatment outcomes for ED.